Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas

American Journal of Clinical Pathology

Volumn 128, Issue 1, 2007, Pages 118-125

  Kim, Yoo Jin ^a   Ketter, Ralf ^a   Steudel, Wolf Ingo ^a   Feiden, Wolfgang ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Ki 67; Meningioma grading; Mitosis; PHH3; Phosphohistone H3; Recurrence

Indexed keywords

HISTONE ANTIBODY; HISTONE H3; KI 67 ANTIGEN; PHOSPHOHISTONE H3 ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; HISTONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MITOSIS INDEX; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; WORLD HEALTH ORGANIZATION; COHORT ANALYSIS; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; MITOTIC INDEX; PHOSPHORYLATION; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 34547130056     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/HXUNAG34B3CEFDU8     Document Type: Article

References (20)

1. Burger PC, Scheithauer BW, Vogel FS, eds. Surgical Pathology of the Nervous System and Its Coverings. New York, NY: Churchill Livingstone; 2002.
2. Louis DN, Scheithauer BW, Budka H, et al. Meningiomas. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press; 2000:176-184. World Health Organization Classification of Tumours.
3. Perry A, Stafford SL, Scheithauer BW, et al. Meningioma grading: an analysis of histological parameters. Am J Surg Pathol. 1997;21:1455-1465.
4. Colman H, Giannini C, Huang L, et al. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol. 2006;30:657-664.
5. Shibata K, Inagaki M, Ajiro K. Mitosis-specific histone H3 phosphorylation in vitro in nucleosome structures. Eur J Biochem. 1990;192:87-93.
6. Shibata K, Ajiro K. Cell cycle-dependent suppressive effect of histone H1 on mitosis-specific H3 phosphorylation. J Biol Chem. 1993;268:18431-18434.
7. Gurley LR, D'anna JA, Barhan SS, et al. Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem. 1978;84:1-15.
8. 2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma. 1997;106:348-360.
9. Hendzel MJ, Nishioka WK, Raymond Y, et al. Chromatin condensation is not associated with apoptosis. J Biol Chem. 1998;18:24470-24478.
10. Baehner R, Weidner N. Enhanced mitotic figure counting in breast carcinomas using a mitosis-specific antibody: anti-phosphohistone-H3 (PHH3) [abstract]. Mod Pathol. 2000;13:17A.
11. Tapia C, Kutzner H, Mentzel T, et al. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol. 2006;30:83-89.
12. Ribalta T, McCutcheon IE, Aldape KD, et al. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol. 2004;28:1532-1536.
13. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20:22-39.
14. Kim YJ, Romeike BFM, Uszkoreit J, et al. Automated nuclear segmentation in the determination of the Ki-67 labeling-index in meningiomas. Clin Neuropathol. 2006;25:67-73.
15. Perry A, Stafford SL, Scheithauer BW, et al. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer. 1998;82:2262-2269.
16. Maier H, Wanschitz J, Sedivy R, et al. Proliferation and DNA fragmentation in meningioma subtypes. Neuropathol Appl Neurobiol. 1997;23:496-506.
17. Ho D, Hsu C, Ting L, et al. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningiomas. Cancer. 2002;94:1538-1547.
18. Torp SH, Lindboe CF, Gronberg BH, et al. Prognostic significance of Ki-67/MIB-1 proliferation. Clin Neuropathol. 2005;24:170-174.
19. Abramovich CM, Prayson RA. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Arch Pathol Lab Med. 1999;123:793-800.
20. Kolles H, Niedermayer I, Schmitt C, et al. Triple approach for diagnosis and grading of meningiomas: histology, morphometry of Ki-67/Feulgen stainings, and cytogenetics. Acta Neurochir (Wien). 1995;137:174-181.